Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk

Cagatay, Tülin; Bingol, ZÜLEYHA; Kiyan, ESEN; Yegin, Zeynep; Okumus, NİGAR; Arseven, Orhan; Erkan, Feyza; Gulbaran, Ziya; Erelel, MUSTAFA; Ece, TURHAN; Cagatay, Penbe; Kilicaslan, Zeki

doi:10.1111/crj.12726

Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk

Cagatay T., Bingol Z., Kiyan E., Yegin Z., Okumus G., Arseven O., ...More

CLINICAL RESPIRATORY JOURNAL, vol.12, no.4, pp.1668-1675, 2018 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 12 Issue: 4
Publication Date: 2018
Doi Number: 10.1111/crj.12726
Journal Name: CLINICAL RESPIRATORY JOURNAL
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1668-1675
Keywords: adalimumab, etanercept, infliximab, Mycobacterium tuberculosis, nontuberculosis mycobacterium, tumor necrozing factor alpha antagonists, RHEUMATOLOGY-BIOLOGICS-REGISTER, ANTI-TNF THERAPY, BRITISH-SOCIETY, ARTHRITIS, MYCOBACTERIAL, INFLIXIMAB, DISEASES, INFECTIONS
Istanbul University Affiliated: Yes

Abstract

ObjectivesTo evaluate the characteristics of patients who developed tuberculosis while receiving tumor necrosis factor-alpha (TNF-) antagonists and the related factors with tuberculosis.